Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab with olaparib within its marketing authorisation as maintenance treatment of advanced squamous non-small-cell lung cancer.
Please note that following on from information provided to NICE by the company in December 2023, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- STA Standard
- ID number:
- 4006
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 29 January 2025 | Discontinued. Please note that following on from information provided to NICE by the company in December 2023, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued |
| 02 January 2024 | Suspended. For information, the company have announced that the Phase III KEYLYNK-008 Trial did not meet its co-primary endpoints in demonstrating an improvement in overall survival (OS) or progression-free survival (PFS) at the second interim analysis, and therefore they will no longer be pursuing a Marketing Authorisation Application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes. |
| 16 November 2023 - 30 November 2023 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 4006 |
| 30 November 2023 | Note - Note added to the project documents |
| 16 November 2023 | In progress. Scoping commencing |
| 10 October 2023 | Note - Note added to the project documents |
| 31 July 2023 | Note - Note added to the project documents |
| 27 March 2023 | Note added to the project documents |
For further information on our processes and methods, please see our CHTE processes and methods manual